CHICAGO/SHANGHAI ¨C Eisai aims to roll out its groundbreaking Alzheimer¡¯s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, a company spokesperson has said.
More convenient Alzheimer¡¯s blood tests expected to be ready next year could help Eisai reach a bigger share of China¡¯s estimated 17 million people with early-stage disease, according to the firm.
¡°China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer¡¯s disease for Eisai,¡± the company spokesperson said. ¡°The potential growth for Leqembi in China is huge.¡±
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.